Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Huperzine for Cognitive and Functional Impairment in Schizophrenia

This study has been completed.
Yale University
Information provided by (Responsible Party):
Scott Woods, MD, Biomedisyn Corporation Identifier:
First received: August 10, 2009
Last updated: February 28, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)